The honeymoon might not be over after all for Conmed Corp. (Utica, N.Y.), which has agreed to acquire privately held Surgiquest Inc. (Milford, Conn.) for $265 million on a cash-free, debt-free basis. After Conmed's third quarter revenues came in $5 million below consensus and the company lowered its 2015 guidance, a Northland Capital Markets analyst said in a Oct. 22 report that "the honeymoon is over" for the surgical device company and lowered its price target on Conmed stock to $44 from $58.

The FDA has approved a biologic bone graft for use in the cervical spine. The i-Factor peptide enhanced bone graft from Cerapedics Inc. (Westminster, Colo.), a private orthobiologics company, was approved as a drug-device combination product for use in anterior cervical disectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. The product represents the first FDA-approved bone graft in the cervical spine and the second FDA-approved bone graft in the spine.

The FDA has approved a biologic bone graft for use in the cervical spine. The i-Factor peptide-enhanced bone graft from Cerapedics Inc., of Westminster, Colo., a private orthobiologics company, got the nod as a drug-device combination product for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease.